Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

One man’s trash may be another man’s treasure, but dumpster diving when investing carries risks. You have to wade through a ...

COLUMBUS — Ohio Attorney General Dave Yost has sent letters to 14 medical spas throughout the state warning them to stop making false or misleading claims about their versions of popular weight-loss ...

Eli Lilly’s experimental pill led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial, the company said on Thursday. Shares ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

The results that exceeded Wall Street expectations pushed the U.S. drugmaker's shares up nearly 13% in premarket trading, ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Ohio Attorney General Dave Yost has sent letters to 14 medical spas throughout the state warning them to stop making false or ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Ohio Attorney General Dave Yost issued a warning to several Ohio medical spas over their alleged claims regarding weight-loss drugs.